WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 563397
CAS#: 51116-01-9
Description: 8-Br-cGMP is an activator of cGMP-dependent protein kinase. It acts by inhibiting the intracellular calcium oscillations of tracheal smooth muscle cells in response to acetylcholine.
MedKoo Cat#: 563397
Name: 8-Br-cGMP
CAS#: 51116-01-9
Chemical Formula: C10H10BrN5NaO7P
Exact Mass: 444.9399
Molecular Weight: 446.08
Elemental Analysis: C, 26.93; H, 2.26; Br, 17.91; N, 15.70; Na, 5.15; O, 25.11; P, 6.94
Synonym: 8-Br-cGMP; 8 Br cGMP; 8BrcGMP;
IUPAC/Chemical Name: sodium (4aR,6R,7R,7aS)-6-(2-amino-8-bromo-6-oxo-3,6-dihydro-9H-purin-9-yl)-7-hydroxytetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-olate 2-oxide
InChi Key: ZJRFCXHKYQVNFK-YEOHUATISA-M
InChi Code: InChI=1S/C10H11BrN5O7P.Na/c11-9-13-3-6(14-10(12)15-7(3)18)16(9)8-4(17)5-2(22-8)1-21-24(19,20)23-5;/h2,4-5,8,17H,1H2,(H,19,20)(H3,12,14,15,18);/q;+1/p-1/t2-,4-,5-,8-;/m1./s1
SMILES Code: [H][C@@]12COP([O-])(O[C@]1([C@H]([C@H](N3C(Br)=NC4=C3NC(N)=NC4=O)O2)O)[H])=O.[Na+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 446.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Iwatani Y, Numa H, Atagi S, Takayama F, Mio M, Kawasaki H. [Mechanisms underlying enhanced vasodilator responses to various vasodilator agents following endothelium removal in rat mesenteric resistance arteries]. Yakugaku Zasshi. 2007 Apr;127(4):729-33. Review. Japanese. PubMed PMID: 17409704.
2: Monfort P, Muñoz MD, Felipo V. Molecular mechanisms of the alterations in NMDA receptor-dependent long-term potentiation in hyperammonemia. Metab Brain Dis. 2005 Dec;20(4):265-74. Review. PubMed PMID: 16382337.
3: Barnstable CJ, Wei JY, Han MH. Modulation of synaptic function by cGMP and cGMP-gated cation channels. Neurochem Int. 2004 Nov;45(6):875-84. Review. PubMed PMID: 15312982.
4: Peluso JJ. Progesterone as a regulator of granulosa cell viability. J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):167-73. Review. PubMed PMID: 12943701.
5: De Oliveira RM, Del Bel EA, Guimarães FS. Effects of excitatory amino acids and nitric oxide on flight behavior elicited from the dorsolateral periaqueductal gray. Neurosci Biobehav Rev. 2001 Dec;25(7-8):679-85. Review. PubMed PMID: 11801293.
6: Melis MR, Argiolas A. Yawning: role of hypothalamic paraventricular nitric oxide. Zhongguo Yao Li Xue Bao. 1999 Sep;20(9):778-88. Review. PubMed PMID: 11245084.
7: Somlyo AV, Matthew JD, Wu X, Khromov AS, Somlyo AP. Regulation of the cross-bridge cycle: the effects of MgADP, LC17 isoforms and telokin. Acta Physiol Scand. 1998 Dec;164(4):381-8. Review. PubMed PMID: 9887962.
8: Smolenski A, Burkhardt AM, Eigenthaler M, Butt E, Gambaryan S, Lohmann SM, Walter U. Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jul;358(1):134-9. Review. PubMed PMID: 9721015.
9: Melis MR, Argiolas A. Role of central nitric oxide in the control of penile erection and yawning. Prog Neuropsychopharmacol Biol Psychiatry. 1997 Aug;21(6):899-922. Review. PubMed PMID: 9380788.
10: Hawkins RD, Zhuo M, Arancio O. Nitric oxide and carbon monoxide as possible retrograde messengers in hippocampal long-term potentiation. J Neurobiol. 1994 Jun;25(6):652-65. Review. PubMed PMID: 8071665.
11: Kreye VA, Hofmann F, Villhauer I. Mode of action of nitrates at the cellular level. Z Kardiol. 1986;75 Suppl 3:16-9. Review. PubMed PMID: 3026102.
12: Kreye VA. Direct vasodilators with unknown modes of action: the nitro-compounds and hydralazine. J Cardiovasc Pharmacol. 1984;6 Suppl 4:S646-55. Review. PubMed PMID: 6083407.
